Drug Profile
SB 249417
Alternative Names: 249417Latest Information Update: 12 May 2004
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Monoclonal antibodies
- Mechanism of Action Factor IX inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Septic shock; Stroke; Thrombosis
Most Recent Events
- 12 May 2004 Discontinued - Phase-I for Stroke in USA (unspecified route)
- 25 Feb 2003 Discontinued - Phase-I for Septic shock in USA (unspecified route)
- 25 Feb 2003 Discontinued - Phase-I for Thrombosis in USA (unspecified route)